MedicaMetrix Announces IV Device Purchase and Appoints Dr. Daniel Larkin Director of Medical Innovation

MedicaMetrix raises funds to commence commercialization of ProstaMetrix device

BOSTON, MASSACHUSETTS (August 3, 2020) – MedicaMetrix, LLC, an innovative medical device company announced today the purchase of an IV securement device invented by Dr. Daniel E. Larkin. Dr. Larkin will also join the company as Director, Medical Innovation bringing his wealth of medical experience. Dr. Larkin is a family medicine doctor in Saint Paul, Minnesota and is affiliated with multiple hospitals in the area.

Dr. Larkin’s IV securement device addresses the need for a safer more systemized process to better manage the infusion site, providing patients maximum comfort and improved quality of care delivery. It does this by reliably stabilizing the IV catheter hub while creating a standard method to organize the infusion tubing.

“We are delighted to welcome Dan to our team and to add his IV securement device to our product portfolio,” said Satish Vankayalapati, Chairman of MedicaMetrix.

“Dan’s IV securement device promises to simplify, stabilize and secure IV catheter access and site management”, said Robert Rudelius, MedicaMetrix CEO. “Our goal is to complete clinical trials and launch the product first quarter 2021.”

About MedicaMetrix
MedicaMetrix develops innovative technologies and device solutions that transform the healthcare status quo, leading to better medical outcomes, streamlined care and enhanced patient experience.

We are leading the development of a new paradigm that transforms the diagnosis, treatment, and management of prostate health by filling the gap between PSA testing and imaging / biopsies. The ProstaMetrix system is a minimally invasive medical device designed to accurately measure the volume of the prostate gland early in the diagnostic process. ProstaMetrix helps physicians assess a patient’s prostate status to better plan and monitor diagnostic procedures, treatments, drug therapies, and guide recommendations for active surveillance versus prostate biopsies.

MedicaMetrix is planning on releasing a number of devices including our SureSet™ Securement device, which secures the catheter hub and infusion tube with a single site bandage and organizes the tubing for easy access and removal. This one simple device streamlines infusion set-up, allows safe and easy access, while reducing variation and improve safety.

Cautionary Statements Concerning Forward-Looking Statements
This press release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events, or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements related to the expected impact of COVID-19 on our business, statements regarding our growth, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our assessment of our internal controls over financial reporting, our visibility at and sponsorship of conferences and educational events. The forwardlooking statements are and will be subject to risks and uncertainties, which may cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements contained in this press release should be evaluated together with the many uncertainties that affect our business and our market, as well as other risks and cautionary statements set forth in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances, or otherwise.

Connect with us

Stay up-to-date with MedicaMetrix news and products.